The findings, published in Cell Reports, offer an example of how computational drug discovery can be applied to targets that have resisted conventional pharmaceutical approaches. Rather than searching only for compounds that bind to the most obvious catalytic sites on a protein, the research focused on the PDZ domain, a structural region involved in protein–protein interactions. These interactions help organize signaling networks inside cells, but they are often broad, shallow or chemically difficult to occupy with conventional drugs.

GIPC1, or GAIP-interacting protein C terminus 1, functions as a scaffold that helps bring signaling molecules and membrane-associated proteins into coordinated complexes. Its PDZ domain can influence the stability, localization and activity of proteins involved in tumor biology. By disrupting this domain, the researchers sought to interfere with signaling that cancer cells use to proliferate, survive stressful conditions and resist therapy. The strategy is particularly relevant to pancreatic cancer, in which malignant cells frequently adapt to treatment and grow within a highly protective tumor environment.

To search for a suitable inhibitor, the team worked with Sravathi AI Technology for IP Sharing, a company based in Bangalore, India. Their computational screening program evaluated nearly 40,000 candidate compounds, prioritizing molecules predicted to interact with the GIPC1 PDZ domain. The process was intended to reduce the time and resources required to examine a large chemical space experimentally. After the initial selection, the researchers performed laboratory testing to determine whether the leading compound could engage GIPC1 and interfere with its biological function.

The resulting inhibitor showed activity in models of pancreatic ductal adenocarcinoma. Blocking GIPC1 reduced cancer-related growth signals and limited the ability of tumor cells to maintain aggressive behavior. In animal studies, treatment with the compound was associated with slower tumor progression and longer survival compared with untreated controls. The investigators also reported that the inhibitor enhanced the effects of gemcitabine, a commonly used chemotherapy drug for pancreatic cancer, suggesting that GIPC1 blockade may eventually become part of a combination-treatment strategy.

Pancreatic cancer remains one of the most challenging malignancies because it is often detected only after it has reached an advanced stage. Tumors can grow around blood vessels and other critical structures, while dense connective tissue can restrict the delivery of medicines. Cancer cells also display extensive molecular diversity, allowing some populations to survive chemotherapy and repopulate the tumor. These features contribute to the disease’s poor prognosis and have created an urgent need for treatments that attack pancreatic cancer through mechanisms distinct from established chemotherapy.

The study also produced early evidence that the experimental drug may affect the tumor microenvironment, the network of noncancerous cells, extracellular matrix components and signaling molecules surrounding a tumor. This environment can shelter malignant cells, suppress immune activity and reduce the penetration or effectiveness of drugs. Although the precise changes induced by GIPC1 inhibition require further investigation, the findings raise the possibility that targeting the protein could make tumors more responsive to chemotherapy or other future treatments.

Artificial intelligence is increasingly being used in drug discovery to predict how molecules may fit into protein structures, estimate binding properties and prioritize candidates for laboratory testing. Its value is especially apparent when researchers are addressing proteins without conventional enzyme pockets or other easily targeted sites. However, computational predictions do not establish that a compound will be effective or safe in a living organism. Candidate molecules must still undergo biochemical validation, cell-based testing, animal studies and, eventually, carefully controlled clinical trials.

“Our study demonstrates that AI can help us identify entirely new therapeutic opportunities against targets that have historically been considered undruggable,” says Debabrata (Dev) Mukhopadhyay, Ph.D., senior author and a cancer researcher at Mayo Clinic in Florida. He cautions that the findings remain preclinical, but says they provide a foundation for the next phase of research. The team must now determine how the inhibitor behaves in the body, establish an effective dose, assess potential toxicity and clarify which patients might benefit from treatment.

The experimental therapy is not approved for use in people and has not yet entered clinical trials. Additional studies will be needed to confirm its selectivity for GIPC1, evaluate possible effects on healthy tissues and test whether its activity can be reproduced across additional pancreatic cancer models. If those investigations are successful, the work could demonstrate that AI-guided targeting of protein–protein interaction domains is a practical route toward new cancer medicines, particularly for tumors that have remained resistant to conventional therapeutic design.

Subject of Research: AI-guided discovery of a small-molecule inhibitor targeting the GIPC1 PDZ domain for pancreatic ductal adenocarcinoma.

Article Title: AI-driven discovery and validation of a GIPC1 PDZ domain inhibitor for pancreatic ductal adenocarcinoma

Web References: Mayo Clinic; Cell Reports study; Mayo Clinic pancreatic cancer information

References: Cell Reports, “AI-driven discovery and validation of a GIPC1 PDZ domain inhibitor for pancreatic ductal adenocarcinoma,” published 31 July 2026.

Keywords: pancreatic cancer, pancreatic ductal adenocarcinoma, GIPC1, PDZ domain, artificial intelligence, AI drug discovery, cancer therapy, gemcitabine, small-molecule inhibitor, tumor microenvironment, Mayo Clinic, preclinical research

Decitabine, an established chemotherapy used for bone marrow disorders and acute myeloid leukemia, works by incorporating into the genome and triggering cell death. However, the researchers explain that DCTPP1 recognizes chemically modified pieces of DNA generated during this process and degrades them, reducing decitabine’s anticancer potency. In prostate cancer cells, where drug responses can become weaker, this degradation may contribute to incomplete therapeutic effects.

To identify ways to disable DCTPP1, the team began with structural biology and chemical screening. They screened 10,000 compounds to find candidates that inhibit DCTPP1 activity. Three distinct chemical classes emerged, suggesting that the protein can be blocked through specific binding interactions.

The researchers then used X-ray crystallography to determine atomic-resolution structures of DCTPP1 bound to these inhibitors. This approach revealed that each inhibitor class occupies a particular nucleotide-binding pocket. With binding modes clarified at the atomic level, the team combined the DCTPP1 inhibitors with decitabine in living prostate cancer cell cultures.

Their experiments indicate that adding DCTPP1 inhibitors boosts decitabine’s effectiveness at killing prostate cancer cells. The findings support the idea that stopping DCTPP1 prevents degradation of decitabine-related DNA modifications, allowing the chemotherapy’s genome-integrating mechanism to proceed more fully.

The study was published June 15 in Proceedings of the National Academy of Sciences as part of NIH-funded research. The authors emphasize that future work will test whether these inhibitor scaffolds can be optimized to further increase potency and potentially extend benefits to additional cancer types beyond prostate cancer.

For patients facing castration-resistant prostate cancer, a form that can metastasize and has a low five-year survival rate, improved drug combinations could be clinically valuable. By repurposing and enhancing an existing therapy rather than developing entirely new drugs, the approach offers a strategic path toward more durable responses.

Funding included support from the National Cancer Institute and additional foundations, reflecting the multi-institutional effort behind the program.

Subject of Research: DCTPP1 protein inhibition to enhance decitabine activity in prostate cancer
Article Title: Newly Identified Inhibitors May Boost Chemotherapy Drug’s Ability to Fight Treatment-Resistant Cancers
News Publication Date: June 15
Web References: https://www.pnas.org/doi/full/10.1073/pnas.2534029123
References: Proceedings of the National Academy of Sciences (June 15)
Image Credits: James Berger
Keywords: DCTPP1; decitabine; prostate cancer; inhibitors; X-ray crystallography; nucleotide-binding pocket; DNA damage; genome integrity; chemotherapy sensitization; treatment resistance